doxazosin

CLINICAL USE

Alpha-adrenoceptor blocker:Hypertension Benign prostatic hyperplasia (BPH)

DOSE IN NORMAL RENAL FUNCTION

Hypertension: 1–16 mg daily BPH: 1–8 mg daily XL preparation: 4–8 mg once daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :547.6 (as mesilate)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :98

%Excreted unchanged in urine &nbsp &nbsp : <5

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1–1.7

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :22/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Antidepressants: enhanced hypotensive effect with MAOIs

Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect

Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect

Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect

Moxisylyte: possibly severe postural hypotension when used in combination

Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect, avoid concomitant use

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

Tags: post-by-auto-php